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The CCAAT box is one of the most common elements in
eukaryotic promoters and is activated by NF-Y, a con-
served trimeric transcription factor with histone-like
subunits. Usually one CCAAT element is present in pro-
moters at positions between 60 and 100, but an
emerging class of promoters harbor multiple NF-Y sites.
In the triple CCAAT-containing cyclin B2 cell-cycle pro-
moter, all CCAAT boxes, independently from their NF-Y
affinities, are important for function. We investigated
the relationships between NF-Y and p300. Chromatin
immunoprecipitation analysis found that NF-Y and p300
are bound to the cyclin B2 promoter in vivo and that
their binding is regulated during the cell cycle, posi-
tively correlating with promoter function. Cotransfec-
tion experiments determined that the coactivator acts
on all CCAAT boxes and requires a precise spacing be-
tween the three elements. We established the order of in
vitro binding of the three NF-Y complexes and find de-
creasing affinities from the most distal Y1 to the proxi-
mal Y3 site. Binding of two or three NF-Y trimers with or
without p300 is not cooperative, but association with the
Y1 and Y2 sites is extremely stable. p300 favors the bind-
ing of NF-Y to the weak Y3 proximal site, provided that
a correct distance between the three CCAAT is re-
spected. Our data indicate that the precise spacing of
multiple CCAAT boxes is crucial for coactivator func-
tion. Transient association to a weak site might be a
point of regulation during the cell cycle and a general
theme of multiple CCAAT box promoters.
The CCAAT box is a widespread promoter element that is
present in many, if not most eukaryotic promoters (1); in the
vast majority of promoters, it is located in either orientation
between 60 and 100 from the transcription start site (2).
The importance of this element has been outlined in innumer-
able functional assays, and indeed, mutations affecting it have
a profound negative effect on the function of neighboring
cis-acting elements. Electrophoretic mobility shift assays
(EMSAs)1 and transfections with highly diagnostic dominant
negative vectors for NF-YA implicated NF-Y as the CCAAT
activator in 500 mammalian promoters (2).2 NF-Y is com-
posed of three subunits, NF-YA, NF-YB and NF-YC, all neces-
sary for DNA binding (3). NF-YA and NF-YC possess large
Q-rich domains that are required for transcriptional activation.
NF-YB and NF-YC are tightly bound through histone-fold mo-
tifs, whose formation is required for NF-YA association and
sequence-specific DNA binding. Circular permutation assays
have clearly shown that NF-Y bends DNA and organizes the
three-dimensional architecture of promoters; it is understood
that NF-Y promotes the binding of neighboring trans-activa-
tors and makes connections with TFIID, contacting several of
the TAFIIs (4). Moreover, NF-Y is able to interface with a well
positioned nucleosome on the major histocompatibility complex
class II Ea promoter and with a chromatin-reconstituted topo-
isomerase II promoter (5, 6).
Coactivators are a large and heterogeneous family of non-
DNA-binding proteins that make use of the platforms repre-
sented by DNA binding factors to access promoters. In general,
coactivators are thought to serve as a bridge for transcription
factors and holoenzyme interactions, having been recruited to
promoters through activation domains. Many coactivators,
such as CBP/p300, PCAF, GCN5, possess an enzymatic activ-
ity, histone acetyltransferase, that adds an acetyl group to
lysines of the N-terminal ends of the core histones (7). The
enzymatic activity is apparently essential for activation func-
tion in many, but not in all systems tested (8–10). In addition
to histones, coactivators also target transcription factors, influ-
encing different aspects of their functions, such as DNA bind-
ing affinity, nuclear localization, or retention (for review, see
Ref. 11). The role of p300/CBP in control of cell growth and
differentiation has been studied in many systems (12). p300/
CBP exerts a profound effect on cell cycle control, as exempli-
fied by the finding that E1A mutants that cannot bind to p300
exhibit defective cellular transformation (13). The p300/
CBPPCAF protein complex might regulate target genes that
are involved in controlling the G1/S transition, such as p21
WAF1
(14). The overexpression of E1A, whose binding to p300/CBP
antagonizes PCAF association, drives cells into S phase (15).
p300/ and cbp/ knockout mice have provided evidence that
p300/CBP proteins are important for cell cycle regulation and
differentiation (16).
Because NF-Y is important for the activation of many pro-
moters, it was natural that connections between this factor and
coactivators emerged. Affinity columns identified interactions
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of the histone-fold motif subunits with human GCN5 (17);
NF-Y-PCAF interactions mediate the potent activation of the
multi-drug resistance-1 promoter upon treatment of human
cells with trichostatin A, and binding to p300 activates the
HSP70 promoter in Xenopus oocytes in the absence of heat
shock or the addition of heat shock factor-1 (18, 19). Among the
many genes activated by NF-Y, an emerging class is repre-
sented by those regulated differently during the cell cycle,
particularly in the G2/M phase. Key regulators such as
CDC25A/B/C, cyclin B1/B2, Cdc2, and topoisomerase II con-
tain multiple CCAAT boxes in their promoters, invariably
shown to be crucial for the proper regulation of these genes
(Ref. 2 and references therein; Refs. 20–26).
Cyclin B is a central regulator for progression from G2 to
mitosis. It associates with the Cdc2 cyclin-dependent kinase 1
and thereby regulates phosphorylation of target proteins (27).
Complex formation between cyclin B and Cdc2 is essential for
G2/M transition. In mammalian cells cyclin B exists in two
isoforms, cyclin B1 and cyclin B2 (28). We have previously
analyzed expression from the cyclin B2 promoter and found
NF-Y to be the major activator (21). Cell cycle-dependent tran-
scription is mediated by a CDE-CHR repressor element (29).
Three NF-Y binding CCAAT boxes in the proximal promoter
spaced 33-bp apart are responsible for more than two-thirds of
the total activity of the cyclin B2 promoter. A large difference in
affinity to NF-Y was detected among these three CCAAT ele-
ments, with the proximal Y3 binding NF-Y with very low
affinity, yet they all equally contributed to the full transcrip-
tional activity of the promoter (21). This raised the possibility
that NF-Y binding is cooperative, either directly, through in-
teractions with intermediate factors such as coactivators, or
else that another factor, for which there is no evidence at the
moment, might bind and activate Y3. To solve this matter, we
present data that dissect the interplay between NF-Y and
p300.
MATERIALS AND METHODS
Analysis of Mutants with Changed Spacing between CCAAT Boxes—
Plasmids derived from the firefly luciferase-expressing wild type cyclin
B2 promoter construct B2-Luc (21, 29) were created by PCR-based
targeted mutagenesis yielding constructs with insertions or deletions
between different CCAAT boxes: Y1–2Plus, CCAATCAACGTGCAGA-
AAGGCTCGAGCTTCCAGTCTAGCCAATGGGTTGCGCGCGCCCTG-
CGTGCGTCTACCCAAT; Y1–2Del, CCAATCAACGTGC2-TCCAGT-
CTAGCCAATGGGTTGCGCGCGCCCTGCGTGCGTCTACCCAAT;
Y2–3Plus, CCAATCAACGTGCAGAAAGGCCTTCCAGTCTAGCCAA-
TGGGTTGCGCGCGCCCTGCTCGAGGTGCGTCTACCCAAT; Y2–
3Del, CCAATCAACGTGCAGAAAGGCCTTCCAGTCTAGCCAAT-
GGGTTGCGCGCGC2TCTACCCAAT (insertions are shown in italics,
deletions were indicated by a2). All plasmids were purified with anion
exchange columns (Qiagen). Mutants were confirmed by DNA sequenc-
ing of both strands.
Transfections and luciferase activity assays to compare wild type
with the above mutant reporters were done by lipofection with Fu-
GENE 6 (Roche Molecular Biochemicals) as previously described (21).
NIH3T3 cells (AC 59; Deutsche Sammlung von Mikroorganismen und
Zellkultur, Braunschweig, Braunschweig, Germany) were transfected
with 1 g of B2-Luci wt or mutant plasmids and with 0.02 g of
pRL-null vector (Promega). Transfection efficiencies were normalized
by the pRL-null cotransfection and by using Renilla luciferase expres-
sion assayed with the dual luciferase system (Promega). The activities
of promoter mutants represent averages of nine assays, which were
standardized as described (21). SaOS-2 cells (ACC 243, from DSMZ)
were cultured as previously described (30). The CMV-p300 expression
plasmid was generously provided by Antonio Giordano. Cells were
transfected using 0.8 g of B2-Luci wt or mutant reporter with 0.016 g
of pRL-null and 2.4 g of CMV-p300 or pcDNA3.1 His C (Invitrogen)
plasmids to keep the total DNA amount constant. Transfections and
Renilla luciferase standardization were done as described above.
Protein Purification, EMSAs, and Footprinting—NF-Y subunits, wt
and mutants, were produced in Escherichia coli and purified on nickel
nitrilotriacetic acid columns (Sigma) as in Liberati et al. (30). His-
tagged p300 was produced in Sf9 cells and purified through nickel
nitrilotriacetic acid-agarose affinity columns. 32P-Labeled fragments
containing the core cyclin B2 promoter (129 to 47) obtained by PCR
were incubated under conditions described in Bolognese et al. (21). In
the EMSA shown in Fig. 3B, we used a monoclonal anti-p300 antibody
(purified mouse anti-p300 14991A was from Pharmingen). For foot-
printing assays, the wt and distance mutant cyclin B2 triple CCAAT
fragments were incubated with NF-Y alone or in combination with p300
(200–400 ng) under the same conditions as in the EMSAs. After the
addition of 5 mM CaCl2, samples were treated with DNase I, extracted
with phenol/ether, precipitated, and analyzed.
Chromatin Immunoprecipitations—Formaldehyde cross-linking and
chromatin immunoprecipitation were performed as described in Wells
et al. (31), with the following modifications. NIH3T3 cells, serum-
starved for 48 h and restimulated for 6, 12, 18, and 24 h, were fixed for
10 min with 1% formaldehyde; after quenching the reaction with 0.1 M
glycine, the cross-linked material was sonicated to 500/800-bp frag-
ments. Immunoprecipitations were performed with protein G-Sepha-
rose (Kirkegaard & Perry Laboratories, Inc.) and 3 g of the YB-
purified rabbit polyclonals, anti-p300 (Santa Cruz SC-585X) and anti-
LBP1 control. The chromatin solution was precleared by adding protein
G-Sepharose for 2 h at 4 °C, separated into aliquots, and incubated with
the antibodies overnight at 4 °C with mild shaking. Before use, protein
G-Sepharose was blocked twice with 1 g/l salmon sperm DNA
sheared at 500-bp lengths and 1 g/l bovine serum albumin, first for
2 h at 4 °C and then overnight. PCR amplifications were performed
with the following primers: cyclin B2 coding, 5-TGTAGACAAGGAAA-
CAACAAAGCCTGGTGGCC, and noncoding, 5 CAGCCACTCCGGTC-
TGCGACA.
RESULTS
p300 Is Bound to the Cyclin B2 Promoter in Vivo—The chro-
matin immunoprecipitation (ChIP) technique is a valuable sys-
tem to detect the binding of transcription factors and coactiva-
tors to promoter sequences. We immunoprecipitated chromatin
derived from exponentially growing NIH3T3 cells with anti-
NF-YB, anti-NF-YC, and anti-p300, and PCR amplifications
with cyclin B2-specific oligonucleotides detected the target pro-
moter in the NF-Y immunoprecipitations (not shown); this is
expected from the previously detected in vitro binding of NF-Y
to the CCAAT boxes and activity of the NF-YA dominant neg-
ative vector (21). Next we wished to determine the association
of NF-Y and p300 to the cyclin B2 promoter during the cell
cycle. NIH3T3 cells were serum-starved and restimulated.
Chromatin was prepared at different time points from these
cells, and ChIPs were performed. Fig. 1 shows that G0 cells
have no NF-Y or p300 on the promoter. The two proteins do not
associate with the cyclin B2 promoter until after 18 h of re-
stimulation, when most cells are completing S phase and cyclin
B2 expression starts. At 24 h, where most cells are in G2/M,
NF-Y and p300 are still largely bound. As a control for earlier
time points, we checked a promoter, JunB, which is rapidly
FIG. 1. Binding of p300 and NF-Y to the cyclin B2 promoter in
vivo. Chromatin immunoprecipitations were performed with NIH3T3
mouse fibroblasts using the indicated antibodies. NIH3T3 serum-
starved cells (G0) were used as well as cells at 6, 12, 18, and 24 h
post-restimulation by the addition of 10% fetal calf serum. Ctl, control.
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induced by serum, and found NF-Y and p300 bound in G0 cells
(Data not shown). We conclude that NF-Y and p300 association
to the cyclin B2 promoter is regulated during the cell cycle,
positively correlating with transcriptional activation of the
gene.
Transcriptional Activation of the Cyclin B2 Promoter by
p300—Because of the p300 interactions with the cyclin B2
promoter observed in ChIP assays in vivo, we decided to inves-
tigate their role in the transcriptional regulation of this gene.
We cotransfected a p300 expression vector and the cyclin B2-
luciferase reporter (21) in NIH3T3 cells. In reporter assays we
observed a reproducible, although not spectacular, activation of
transcription (Fig. 2A) that is well in line with numerous re-
ports of similar experiments performed in other promoter sys-
tems (8–10). To verify the CCAAT dependence of the p300
activation, we used several mutant constructs with alterations
in the Y1, Y2, and/or Y3 pentanucleotides described previously
(21): Fig. 2A shows that compared with the wt cyclin B2, all
mutant constructs are variously crippled in transcription and,
most importantly, in p300 activation. In particular, mutation of
the Y1/Y2 high affinity NF-Y sites and change of the all three
Y1–3 boxes are essentially refractory to the activity of p300
overexpression. Additionally, mutation of Y3, which is a poor
NF-Y binding site, is also severely down in p300-stimulated
transcription.
It is well known that correct spacing between different tran-
scription factors is a crucial aspect in promoter proficiency. The
three CCAAT boxes of the cyclin B2 promoter are aligned, with
a conserved spacing of 33 base pairs between them. Because
the presence of all three CCAAT boxes is important for optimal
transcription and for p300 activation, we figured that cyclin B2
transcriptional regulation represents a good system to study
the role of activator alignment for p300 function. The distance
between the three CCAAT sites is 33 base pairs, which repre-
sents an almost perfect alignment of the three binding ele-
ments on the same side of the double helix. We derived a set of
mutants in which the spacing between Y1/Y2 and Y2/Y3 was
altered, either by eliminating 10 base pairs, 1 turn of the
double helix, or adding 5 base pairs. In the first case one
expects to be at the limit of simultaneous NF-Y/CCAAT bind-
ing, based on experiments performed on the double CCAAT
boxes of the human -globin promoter (32). In the second, the
two NF-Y sites would be positioned on opposite sides of the
DNA helix (see the scheme in Fig. 2B). These mutants were
tested in the cotransfection assays used above with and with-
out p300 overexpression. Fig. 2B shows that all distance
mutants exhibited decreased activity, about 3/4-fold lower
than wt, even without p300 cotransfection. More importantly,
p300-dependent activation was reduced by about 2/3-fold but
not completely abolished. Interestingly, the most affected
mutant was Y2/Y3Plus, which is expected to affect the inter-
actions between the two lowest affinity NF-Y sites. Overall,
these data indicate that p300 activates cyclin B2 transcrip-
tion by acting on intact and correctly spaced CCAAT boxes.
Despite their differences in relative NF-Y affinities, all three
CCAAT elements are important for p300-dependent
activation.
Association of p300 to Multiple NF-Y/CCAAT Complexes—
The results obtained with in vivo assays prompted us to set up
an in vitro system with recombinant proteins to dissect the
interplay between p300 and the NF-Y binding to the three
CCAAT boxes in the cyclin B2 promoter. Recombinant NF-Y
proteins were purified from E. coli, and p300 was purified from
baculovirus. These reagents were employed in EMSAs. It
should be noted that NF-Y-p300 direct interactions in solution
were described in Xenopus (18), but we found no evidence of
such interactions under our immunoprecipitation conditions.3
3 G. Caretti and R. Mantovani, manuscript in preparation.
FIG. 2. Activation of cyclin B2 by p300. A, the schemes of the single, double, and triple CCAAT mutants are represented on the left, which
are the results from reporter assays after transfection in NIH3T3 cells. B, equivalent to the upper panel with distance mutants between the three
CCAAT boxes. Standard deviations were lower than 20%.
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Initially, we wished to test the possibility that p300 directly
binds to DNA-bound NF-Y. A cyclin B2 fragment of 200 base
pairs containing the three Y boxes was labeled and used with
increasing amounts of NF-Y in the absence or presence of 20 ng
of p300 (Fig. 3A, lanes 1–4 and 5–8, respectively). As expected,
multiple bands are generated with NF-Y, corresponding to the
formation of complexes with one, two, or three trimers bound to
the Y boxes (see below). Two types of information were man-
ifest from this experiment. (i) At high NF-Y concentrations a
slow migrating complex is observed only in the presence of
p300 (compare lanes 4 and 8); (ii) at low NF-Y concentrations
the addition of p300 induces an increase of double CCAAT
binding (compare lanes 2 and 3 with lanes 6 and 7). In
parallel, the same amount of proteins was incubated with
probes of identical lengths containing mutations in either Y1
and Y2 (Fig. 3A, lanes 9–17) or all three CCAAT boxes (Fig.
3A, lanes 17–24). With the Y1/Y2m probe a single band was
generated only at high NF-Y concentrations, representing a
single NF-Y bound to the low affinity Y3. This complex is not
affected by the addition of p300. With the Y1/Y2/Y3m probe,
no interaction was observed in the presence or absence of
p300 even at high NF-Y concentrations. To verify the effect of
p300 addition, we performed supershift EMSAs; as shown in
Fig. 3B, formation of the upper, slow migrating complex was
partially inhibited by the addition of anti-p300 antibodies,
with the appearance of the non-p300 complexed NF-Y single
and double complexes (compare lane 4 with lane 2). A the
same time, the addition of anti-p300 had no effect on the
NF-Y complexes, much like an irrelevant anti-Gata antibody
on the NF-Yp300 complexes (Fig. 3B, lanes 3 and 5). Having
detected a complex of discrete mobility between NF-Y and
p300 on the wt cyclin B2 probe, we used a recombinant NF-Y
trimer deleted of domains outside of the homology domains of
NF-YA/B/C: Fig. 3C shows that unlike wt NF-Y, which can be
bound by p300, the YA9-YB4-YC5 mutant (33, 34) is incapa-
ble of doing so.
Taken together these results indicate that a complex can be
formed in vitro between NF-Y and p300 provided that (i) mul-
tiple CCAAT boxes are present and bind the bridging NF-Y,
and (ii) domains outside the histone-fold motifs of NF-YB-
NF-YC and the conserved part of NF-YA are present. Binding
of p300 apparently favors NF-Y-DNA interactions.
Lack of Cooperativity of the NF-Yp300 Complex—Our anal-
ysis on the double CCAAT box of the -globin promoter sug-
gested that if a certain spacing is respected (32 bp), then
cooperative binding of NF-Y molecules is possible, mainly
thanks to the presence of Q-rich regions of NF-YA and NF-YC.
In other systems, NF-Y is capable of improving the DNA bind-
ing affinity of neighboring factors, forming extremely stable
DNA-protein complexes (3). Because of the presence of a 33-bp
spacing between all three Y boxes, we considered the possibility
that three NF-Ys could bind DNA cooperatively; alternatively,
cooperativity could be mediated by the association of the coac-
tivator. To investigate this point, we performed off-rate EMSA
experiments with the cyclin B2 probe used above. We incubated
two different quantities of NF-Y in two sets of assays for 30
min, until the binding equilibrium was reached, then added a
large 200-fold excess of an unlabeled oligonucleotide con-
taining the high affinity CCAAT box of the major histocom-
patibility complex class II Ea promoter. After the indicated
periods of time, an aliquot of the sample was loaded on a
running polyacrylamide gel. At low doses (Fig. 4A, lanes 1–5),
under conditions where only single and double CCAAT bind-
ing is observed, the upper band, corresponding to Y1-Y2
occupation (see below), was rapidly competed (compare lanes
1–3), whereas the single interaction only slowly decreased.
This behavior is not indicative of a cooperative effect, because
in the latter case, we would have observed a slower decrease
of the upper complex compared with the lower, single CCAAT
binding activity. At higher NF-Y amounts (Fig. 4A, lanes
6–10), the triple interaction appeared. In this case, double
and single CCAAT binding was still observed at late time
points (lanes 9 and 10), but triple binding was rapidly com-
peted, being minimal after 15 min (compare lanes 6–8). Be-
cause of the persistence of NF-Y binding at relatively late
points (90 min in lanes 5 and 10), we extended the off-rates to
4, 8, 16, and 24 h, starting with NF-Y concentrations that
generate triple binding. Fig. 4B shows that double and single,
but not triple NF-Y binding, persisted after 24 h of incubation
with the competing oligonucleotide. By comparison, we per-
formed a parallel experiment in the absence of unlabeled
competitor, which showed a slower off-rate for the triple
complex (Fig. 4B, compare lanes 1–3 with 6–8). These latter
experiments reinforce the notion that CCAAT binding by
NF-Y to high, that medium affinity sites are stunningly sta-
FIG. 3. Binding of NF-Y and p300 to the triple CCAAT cyclin B2-promoter. A, EMSA analysis of the wt cyclin B2 region (lanes 1–8), the
Y1-Y2m (lanes 9–17), and triple CCAAT mutant (lanes 18–25) with increasing doses of NF-Y (0.3 ng: lanes 1, 5, 10, 14, 18, 22; 1 ng: lanes 2, 6, 11,
15, 19, 23; 3 ng: lanes 3, 7, 12, 16, 20, 24; 10 ng: lanes 4, 8, 13, 17, 21, 25) in the absence (lanes 1–4, 10–13, 18–21) or presence (lanes 5–8, 14–17,
22–25) of 100 ng of p300. In lane 9 p300 alone was incubated with DNA. B, EMSA supershift. Same as A in lanes 4 and 8, except that we added
anti-p300 (500 ng in lanes 3 and 4) or anti Gata1 (same amount in lanes 5) for 30 min before the addition of p300. Ctl, control. C, EMSA of wt NF-Y
trimer (lanes 3–4) or mutants YA9/YB4/YC5 (30) were incubated with wt cyclin B2 DNA in the absence (lanes 1 and 3) or presence of p300 (lanes
2–4).
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ble, and that no cooperativity is observed in vitro with either
Y1-Y2 or the low affinity Y3.
One possibility to explain the transfection data of Fig. 2
could be that cooperativity is mediated by p300. We therefore
performed the same type of off-rate EMSAs in the presence of
p300 using as a competitor a long oligonucleotide comprising
the Y1-Y2 boxes (Fig. 4C, lanes 1–8) or a Y1 oligonucleotide
(Fig. 4C, lanes 9–16). Results indicate that the addition of the
coactivator had no effect on the stability of the NF-Yp300 or
NF-Y triple, double, or single complexes using the Y1-Y2
competitor (compare lanes 1–4 with 5–8). Using the short Y1
oligonucleotide as competitor, no effect was observed on the
triple complexes, whereas a modest effect is observed on the
double complex (compare lanes 13–16 with 9–12). Most likely
this is due to the less efficient competition of the single
CCAAT oligonucleotide compared with the double CCAAT
boxes. Collectively, these results argue against the idea
that multiple NF-Ys with or without p300 are capable of
forming higher order complexes that bind DNA cooperatively
in vitro.
EMSA and Footprinting Analysis of Distance Mutants be-
tween Y Boxes—The functional data on the distance mutants
shown in Fig. 2 lead us to analyze the role of spacing on NF-Y
interactions with and without p300. Initially, we verified the
NF-Y binding capacity in EMSA experiments with probes con-
taining the alterations described in Fig. 2. Results in Fig 5
show that, with the exception of Y1-Y2Del, all other mutants
showed normal interactions with NF-Y. The apparent difficulty
in forming double CCAAT box-NF-Y complexes observed with
the latter mutant (Fig. 5, compare lane 3 with 1) was not
unexpected, because the distance between Y1 and Y2 becomes
23 base pairs, which is the lower limit for simultaneous NF-Y
binding (30).
Next we switched to footprinting analysis of these five
probes after incubation with NF-Y and p300 (Fig. 6). Panel A
shows that increasing concentrations of NF-Y progressively
protects Y1 and Y2, but hardly Y3 (Fig. 6A, lanes 1–4).
However, in the presence of p300, protections over Y2 and Y3
are observed already at lower NF-Y concentrations (Fig. 6A,
compare lanes 2–4 with lanes 5–7). Furthermore, protection
of Y3 is only observed with p300 (Fig. 6A, compare lanes 4
and 7). In addition to CCAAT protections, NF-Y and NF-
Yp300 also generated hypersensitive sites at the 5 of Y1,
FIG. 5. Binding of NF-Y to the CCAAT distance mutants. EMSA
analysis of NF-Y binding (2 ng) to cyclin B2 promoter mutants derived
from plasmids described in Fig. 2.
FIG. 4. Lack of DNA binding cooper-
ativity with NF-Yp300 complexes. A,
off-rates EMSA analysis of NF-Y and NF-
Yp300 complexes on the cyclin B2 pro-
moter. 2 ng (lanes 1–5) or 10 ng (lanes
6–10) of NF-Y were incubated with the
cyclin B2 probe until equilibrium was
reached and then challenged for the indi-
cated times with 100-fold molar excess of
Y1 CCAAT-oligonucleotide (21). B, as in
A, except that samples with 10 ng of NF-Y
were incubated for the indicated hours in
the presence (lanes 1–5) or absence (lanes
6–10) of the unlabeled competitor (comp.).
C, same as A, except that NF-Y (2 ng) was
incubated in the absence (lanes 1–4 and
9–12) or presence (lanes 5–8 and 13–16)
of 100 ng of p300. In lanes 1–8 a long
oligonucleotide containing both Y1 and
Y2 (21) was used as a cold competitor;
lanes 9–16 used the Y1 oligonucleotide.
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between Y1 and Y2 and between Y2 and Y3. Note that p300
alone was incapable of DNA binding (Fig. 6A, compare lanes
1 and 8 with lane 7). The same set of experiments was
performed on the four mutant promoters; Fig. 6B shows the
Y1-Y2Del probe, with weaker protections over Y2, no protec-
tion on Y3, and absence of hypersensitive sites between
Y1-Y2 and Y2-Y3. On the other hand, the binding on Y1 is
apparently normal (Fig. 6B, compare lanes 1–3 and 4–6 with
lane 8). Fig. 6C shows the 1–2Plus probe, which has essen-
tially wt-like patterns of NF-Y protections and hypersensi-
tive sites, with a decrease of the hypersensitive site between
Y2-Y3 (compare lanes 1–4 in Fig. 6A with lanes 1–4 in Fig.
6C); the addition of p300 has negligible effects on Y1 or Y2
binding but clearly decreases Y3 interactions (Fig. 6C, lanes
5–7 and 9). With the Y2–3Del probe, binding of Y3 and to a
lesser extent Y2, but not Y1, is decreased; the Y2–3 hyper-
sensitive site is also abolished (Fig. 6D). Finally, with the
Y2–3Plus, binding of Y1 and Y2 is normal as well as the Y1–2
hypersensitive site, but Y3 binding is negligible; the addition
of p300 has essentially no effect on NF-Y binding on Y3 but
has a modest effect on Y2 (Fig. 6E, compare lanes 2–4 with
5–7). Altogether, these results indicate p300 acts on NF-Y
bound to Y1 and Y2 to increase the otherwise very low affin-
ity for the Y3 CCAAT; alterations of the correct spacing
between the Y1-Y2 or Y2-Y3 CCAAT boxes abolish the p300-
facilitation effect.
DISCUSSION
In this study we investigated the relationship between NF-Y
and p300 on the cyclin B2 promoter that is active in the G2/M
phase of the cell cycle. We found that p300 activates in a
manner that requires a precise spacing between the three
CCAAT boxes. Indeed, NF-Y and the coactivator are bound to
the promoter in vivo in a cell cycle-dependent way. In vitro the
order of binding of three NF-Y protein complexes is Y1 Y2
Y3, with decreasing affinities from the most distal to the prox-
imal site. The binding of two or three NF-Y molecules with or
without p300 is not cooperative. However, p300 favors the
association of NF-Y to the proximal site, and the distance
between the three CCAAT boxes is crucial for this activity. We
conclude that the precise alignment of multiple CCAAT boxes
is crucial for coactivator function.
NF-Y Binding to Multiple CCAAT Boxes—A recent analysis
of 1031 human promoters indicated that the CCAAT box is
present in 65% of them (1). We have catalogued 500 CCAAT
promoters regulated by NF-Y and found that the majority
contain only one CCAAT box, either in the forward or reverse
orientation. In general, NF-Y cooperates with neighboring
factors to regulate gene expression. In inducible systems,
such as those of the heat shock, endoplasmic reticulum stress
response, and genes involved in cholesterol metabolism,
NF-Y teams up with heat shock factor, ATF6, and sterol
regulatory element binding protein. In the major histocom-
patibility complex class II genes setting, NF-Y cooperates
with the regulatory factor X box trimer (Ref. 3 and references
therein; Refs. 18 and 34). The mechanism of the cooperative
effect has been studied and, baring the NF-Y-C/EBP connec-
tions on the albumin promoter, in all other cases NF-Y me-
diates a profound increase in DNA-binding affinity of the
neighboring factor.
Alterations in the spacing between the CCAAT boxes and
nearby sites provoke a decrease and sometimes abolition of the
activation potential. In cell cycle-regulated promoters, NF-Y is
essential for the timing of activation (35, 36) and repression
(37, 38). In the case of G1/S promoters, NF-Y cooperates with
E2Fs; in G2/M promoters NF-Y binding CCAAT boxes are
found near the CDE-CHR element (29, 37–39). Biochemically,
it is unclear at what level the cooperation is exerted. Many cell
cycle promoters are peculiar in that they contain at least two
and sometimes more NF-Y binding sites, in particular in pro-
moters of key G2/M cell cycle regulators Cdc2, topoisomerase
II, CDC25C, and cyclin B1/B2 (Table I). The distance between
these elements is (i) highly conserved among species and (ii)
relatively constant; in the case of CDC25C, three CCAAT boxes
are spaced 32 bp apart, in cyclin B2 the distances are 33 bp, in
FIG. 6. Footprinting analysis of NF-Yp300 binding to the cyclin B2 CCAAT box distance mutants. Increasing concentrations of NF-Y
(5, 15, 50 ng) in the absence (lanes 2–4) or in the presence of 500 ng of p300 (lanes 5–7) were used with the indicated probes in A–E. In lanes 1 and
9 no protein was added; lanes 8 contained only p300.
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Cdc2 two CCAAT elements are spaced by 32 bp. Promoters for
which both human and mouse sequences are available show
that the sequences of NF-Y binding sites as well as their
distance is strictly conserved. Especially in CDC25C and cyclin
B2 mouse and human promoters nucleotides in between
CCAAT boxes are not conserved, contrasting the sequence
identity of and distance between NF-Y binding elements (32).4
In all the promoters mentioned above, the affinities of NF-Y for
the individual CCAAT sites differ; in CDC25C one of the
CCAAT boxes is not even a perfect pentanucleotide. In cyclin
B2 it is apparent that between Y1 and Y3 there is a 50-fold
difference in binding affinity, yet the integrity of Y3 is as
important as the high affinity Y1 binding in terms of function.
The cyclin B2 systems is also conspicuous for another reason;
that is, the NF-Y sites are apparently sufficient on their own to
activate this promoter essentially without the need of addi-
tional factors. This is unlike the other systems tested so far, in
which NF-Y is unable to activate alone. In a previous study on
the -globin promoter, we found that NF-Y binding to double
CCAAT boxes spaced by 27 nucleotides was not cooperative
unless an extra 5 nucleotides were added. In such a case, a
complex formed by two NF-Y trimers bound to the two sites
was much more stable in off-rate experiments thanks to the
presence of the NF-YA and NF-YC glutamine-rich domains
(30). The distance of 32 nucleotides predicts that the two
CCAAT boxes are on the same side of the DNA double helix,
which has an average periodicity of 10.5 and is somewhat
dependent upon the sequence. Thus, we expected that the
binding of NF-Y to the triple CCAAT elements of cyclin B2
could be itself cooperative in our in vitro EMSAs. This is not the
case (Fig. 4). It is possible that the lack of cooperativity is due
to the extra nucleotide present between the cyclin B2 CCAAT
boxes or to the intervening sequences. Nevertheless, it is clear
that the stability of the Y1-Y2NF-Y complexes is extremely
high, with a half-life of 24 h in vitro. Thus, one is tempted to
conclude that unlike the situation when NF-Y finds another
transcription factor nearby, cooperativity at the DNA binding
level is not required when two or more NF-Y sites are aligned
on the promoter, even in the presence of CCAAT boxes that do
not conform to an optimal binding consensus. Yet, the perfect
alignment of the three sites is clearly required for optimal
promoter function (Fig. 2). Optimal transcription then results
from additional contacts.
Bending and phasing assays revealed that NF-Y distorts and
rotates DNA in a way that is reminiscent of histones bound to
DNA in the nucleosomal structure (30, 39, 40). The stunningly
slow off-rates observed in this study are a premiere for se-
quence-specific transcription factors and can only be compared
with the highly stable nucleosomal structures. Indeed, two of
the NF-Y subunits, NF-YB and NF-YC, have histone-like fea-
tures, as predicted from amino acid alignments, o-phenanthro-
line footprinting, and structure-function analyses and, most
importantly, as detailed by recent crystallographic studies (41).
A spacing of 32/33 nucleotides, thereby an alignment on the
same side of the double helix, is in keeping with three CCAAT
boxes forming a heminucleosomal structure, as indicated by
Fig. 7. The minimal platform recognized by coactivators is
likely to be NF-Y binding to Y1 and Y2, with additional con-
tacts made on Y3 once p300 has been recruited onto the
promoter.
Activity of p300 on Cell Cycle Promoters—p300/CBP proteins
are coactivators involved in the activation of a large number, if
not all, the polymerase II-transcribed genes. In particular,
p300 and CBP are targets of the adenovirus E1A oncoprotein;
their role in cell cycle control has been shown by the finding
that E1A mutants that cannot bind to p300 exhibit defective
cellular transformation (13). The overexpression of E1A, which
antagonizes PCAF binding to p300/CBP, drives cells into S
phase (14). E1A is also known to affect the binding of pocket
proteins to the E2F transcription factors that are associated
with genes modulated in the cell cycle. Recent experiments on
an E2F-regulated promoter show that p300 is important for the
cell cycle-regulated expression of dihydrofolate reductase (42).
The p300/CBPPCAF protein complex is believed to regulate
target genes that are involved in controlling the G1/S transi-
tion, such as p21WAF1 (15). Activity of p300/CBP has been
studied in a number of systems, with particular focus on their4 M. Wasner and K. Engeland, unpublished information.
FIG. 7. Scheme for NF-Yp300 interactions on the cyclin B2
promoter.
TABLE I
List of cell cycle promoters with multiple CCAAT boxes spaced by 31/33 nucleotides
Sequences from cyclin B2 were from Bolognese et al. (21), CDC25C and Cdc2 were from Haugwitz et al. (32) and Zwicher et al. (38, 39), cyclin
B1 was from Farina et al. (22), thymidine kinase was from Arcot et al. (48), and RRR2 was from Park and Levine (49).
NF-Y and p300 in Cell Cycle Regulation6648
 at U
N
IV
ERSITA
 D
I M
O
D
EN
A
 on M
ay 6, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
acetyltransferase enzymatic activity. We find that the positive
role of p300 on NF-Y function is exerted through an increase in
DNA affinity, mostly observed on the weak Y3 binding site. To
the best of our knowledge, this is the first such demonstration
for p300 binding on multiple sites for the same factor. Essen-
tially three types of action are supposed to be exerted by p300/
CBP; (i) the protein serves as a platform, a bridge, through
which the direct interactions with multiple DNA binding acti-
vators are supported; recruitment of p300/CBP stabilizes the
otherwise weak binding of these factors or even makes them
possible. In keeping with this, interactions of p300/CBP with
many transcription factors have been mapped in one and some-
times multiple subdomains of the coactivators. Evidence for
this mechanism is still largely circumstantial, and the bio-
chemical dissection of this mechanism on DNA was obtained
only on the -interferon promoter (43). (ii) Once on a promoter,
p300/CBP proteins modify the chromatin structures nearby the
sites by virtue of their histone acetylation activity, rendering
nucleosomes more “accessible” to the general transcription
apparatus. (iii) The same histone acetyltransferase activity
would be used to increase the affinity of the DNA binding
factor for the targeted sequence. This latter property is less
well understood. In many cases, in fact, the opposite happens;
acetylation of high mobility group(I) inhibits formation of the
enhanceosome on the -interferon promoter (43). In the case
of p53, whose function is positively affected by p300, acety-
lation apparently affects recruitment of p300/CBP (44). In-
terestingly, in keeping with these latter results, we find that
p300 acetylates NF-YB and that this modification increases
NF-Y-p300 interactions.3 In many promoters, the histone
acetyltransferase activity of p300/CBP is apparently dispen-
sable (8–10); p300/CBP and PCAF cooperate with members
of the MyoD family of muscle transcription factors in modu-
lating the expression of downstream myogenic factors, in-
cluding myogenin and MEF2, leading to terminal withdrawal
from the cell cycle of myotubes (45, 46). The p300 histone
acetyltransferase domain is dispensable for MyoD-dependent
transcription, suggesting that the “bridging” mechanism is
predominant in this case.
One important result that stems from the ChIP analysis is
that the cyclin B2 promoter is devoid of NF-Y and p300 in cells
arrested in G0, and the two activators become bound only in
S-phase, when the gene starts to be activated. This was not
obvious, considering the presence of NF-Y on the cyclin B1
promoter during mitosis, recently described in HeLa cells (47).
Moreover, other promoters are indeed bound by NF-Y in G0
cells, suggesting regulation of promoter selectivity in this
phase. These data rule out alternative scenarios that could
have been envisaged; (i) p300 would be absent from the
promoter in G1 and early S, when the promoter is silent, and
be recruited in late S through interactions with a pre-bound
NF-Y, constitutively associated through the cycle; (ii) it
would be co-resident with the Y1-Y2 NF-Y throughout the
cell cycle and only become active in late S, to promote Y3
binding. Open questions remain as to the regulation of NF-Y
promoter association through the cell cycle. It is possible that
additional signals, most likely post-translational modifica-
tions such as phosphorylations and acetylations, regulate
this process.
A corollary to the model in Fig. 7 is represented by the
possibility that NF-Y binding to Y3 is transitorily regulated
by p300 during the G2/M phase of the cell cycle; in vivo
footprinting analysis show a much stronger protection of
these two boxes in cycling cells as compared with Y3 (21).
Unfortunately, the ChIP technique does not allow us to dis-
criminate the presence of two or three molecules of NF-Y
bound to cyclin B2 in vivo. With the present limitations of our
assays it is not possible to tell whether one or more p300
molecules become associated with the promoter. Y3 is posi-
tioned just downstream of the two major start sites of this
TATA-less promoter and in proximity of the CDE-CHR ele-
ment recently described (29), which is also protected in vivo.
Therefore, it is likely that it represents a key point for reg-
ulation of interactions with the proteins binding to the CDE-
CHR, whose elusive biochemical nature precludes further
studies at the moment. At the same time these elements may
be an entry site for the general transcriptional machinery. It
is also possible that the low affinity for NF-Y at Y3 has
evolved by fluctuation of the sequences flanking CCAAT to
create the possibility of an on-off system, less likely to happen
on high affinity sites such as Y1. This type of mechanisms
might not be restricted to the cyclin B2 promoter but rather
a constant for cell cycle and, in general, growth-regulated
promoters.
Acknowledgments—We thank Lee Kraus for p300 baculovirus and
Antonio Giordano for providing plasmids.
REFERENCES
1. Suzuki, Y., Tsunoda, T., Sese, J., Taira, H., Mizushima-Sugano, J., Hata, H.,
Ota, T., Isogai, T., Tanaka, T., Nakamura, Y., Suyama, A., Sakaki, Y.,
Morishita, S., Okubo, K., and Sugano, S. (2001) Genome Res. 11, 677–684
2. Mantovani, R. (1998) Nucleic Acids Res. 26, 1135–1143
3. Mantovani, R. (1999) Gene 239, 15–27
4. Frontini, M., Imbriano, C., diSilvio, A., Bell, B., Bogni, A., Romier, C., Moras,
D., Tora, L., Davidson, I., and Mantovani, R. (2002) J. Biol. Chem. 277,
5841–5848
5. Caretti, G., Motta, M. C., and Mantovani, R. (1999) Mol. Cell. Biol. 19,
8591–8603
6. Coustry, F., Hu, Q., de Crombrugghe, B., and Maity, S. N. (2001) J. Biol. Chem.
276, 40621–40630
7. Sterner, D. E., and Berger, S. H. (2000) Microbiol. Mol. Biol. Rev. 64, 435–459
8. Zeng, X., Lee, H., Zhang, Q., and Lu, H. (2001) J. Biol. Chem. 276, 48–52
9. Harton, J. A., Zika, E., and Ting, J. P. (2001) J. Biol. Chem. 276, 38715–38720
10. Song, C-Z., Keller, K., Murata, K., Asano, H., and Stamatoyannopoulos, G.
(2002) J. Biol. Chem. 277, 7029–7036
11. Kouzarides, T. (2000) EMBO J. 19, 1176–1179
12. Goodman, R. H., and Smolik, S. (2000) Genes Dev. 14, 1553–1577
13. Wang, H.-G. H., Moran, E., and Yacuik, P. (1995) J. Virol. 69, 7917–7924
14. Yang, X. J., Ogryzko, V. V., Nishikawa, J., Howard, B. H., and Nakatani, Y.
(1996) Nature 382, 319–324
15. Missero, C., Calautti, E., Eckner, R., Chin, J., Tsai, L. H., Livingston, D. M.,
and Dotto, G. P. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5451–5455
16. Yao, T., Oh, S. P., Fuchs, M., Zhou, N., Ch’ng, L., Newsome, D., Bronson, R. T.,
Li, E., Livingston, D. M., and Eckner, R. (1998) Cell 93, 361–372
17. Currie, R. A. (1998) J. Biol. Chem. 273, 1430–1434
18. Li, Q., Herrler, M., Landsberger, N., Kaludov, N., Ogryzko, V. V., Nakatani, Y.,
and Wolffe, A. P. (1998) EMBO J. 17, 6300–6315
19. Jin, S., and Scotto K. W. (1998) Mol. Cell. Biol. 18, 4377–4384
20. Adachi, N., Nomoto, M., Kohno, K., and Koyama, H. (2000) Gene 245, 49–57
21. Bolognese, F., Wasner, M., Lange-zu Dohna, C., Gurtner, A., Ronchi, A.,
Muller, H., Manni, I., Mossner, J., Piaggio, G., Mantovani, R., and
Engeland, K. (1999) Oncogene 18, 1845–1853
22. Farina, A., Manni, I., Fontemaggi, G., Tiainen, M., Cenciarelli, C., Bellorini,
M., Mantovani, R., Sacchi, A., and G. Piaggio. (1999) Oncogene 18,
2818–2827
23. Korner, K., and Muller, R. (2000) J. Biol. Chem. 275, 18676–18681
24. Krause, K., Haugwitz, U., Wasner, M., Wiedmann, M., Mossner, J., and
Engeland, K. (2001) Biochem. Biophys. Res. Commun. 284, 743–750
25. Taylor, W. R., DePrimo, S. E., Agarwal, A., Agarwal, M. L., Schonthal, A. H.,
Katula, K. S., and Stark, G. R. (1999) Mol. Biol. Cell 19, 3607–3622
26. Yun, J., Chae, H. D., Choy, H. E., Chung, J., Yoo, H. S., Han, M. H., and Shin,
D. Y. (1999) J. Biol. Chem. 274, 29677–29682
27. Gautier, J., Minshull, J., Lohka, M., Glotzer, M., Hunt, T., and Maller, J. L.
(1990) Cell 60, 487–494
28. Lew, D. J., Dulic, V., and Reed, S. I. (1991) Cell 66, 1197–1206
29. Lange-zu Dohna, C., Brandeis, M., Berr, F., Mossner, J., and Engeland, K.
(2000) FEBS Lett. 484, 77–81
30. Liberati, C., di Silvio, A., Ottolenghi, S., and Mantovani, R. (1999) J. Mol. Biol.
285, 1441–1455
31. Wells, J., Boyd, K. E., Fry, C. J., Bartley, S. M., and Farnham, P. J. (2000) Mol.
Cell. Biol. 20, 5797–5807
32. Haugwitz, U., Wasner, M., Wiedmann, M., Spiesbach, K., Rother, K., Mossner,
J., and Engeland, K. (2002) Nucleic Acids Res. 30, 1967–1976
33. Bellorini, M., Zemzoumi, K., Farina, A., Berthelsen, J., Piaggio, G., and Man-
tovani, R. (1997) Gene 193, 119–125
34. Zemzoumi, K., Frontini, M., Bellorini, M., and Mantovani, R. (1999) J. Mol.
Biol. 286, 327–337
35. Yoshida, H., Okada, T., Haze, K., Yanagi, H., Yura, T., Negishi, M., and Mori,
K. (2001) Mol. Cell. Biol. 21, 1239–1248
NF-Y and p300 in Cell Cycle Regulation 6649
 at U
N
IV
ERSITA
 D
I M
O
D
EN
A
 on M
ay 6, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
36. van Ginkel, P. R., Hsiao, K. M., Schjerven, H., and Farnham, P. J. (1997)
J. Biol. Chem. 272, 18367–18374
37. Luger, K., Mader, A. W., Richmond, R. K., Sargent, D. F., and Richmond, T. J.
(1997) Nature 389, 251–262
38. Zwicker, J., Gross, C., Lucibello, F. C., Truss, M., Ehlert, F., Engeland, K., and
Muller, R. (1995) Nucleic Acids Res. 23, 3822–3830
39. Zwicker, J., Lucibello, F. C., Wolfraim, L. A., Gross, C., Truss, M., Engeland,
K., and Muller, R. (1995) EMBO J. 14, 4514–4522
40. Liberati, C., Ronchi, A., Lievens, P., Ottolenghi, S., and Mantovani, R. (1998)
J. Biol. Chem. 273, 16880–16889
41. Romier, C., Cocchiarella, F, Mantovani, R., and Moras, D. (2003) J. Biol. Chem.
278, 1336–1345
42. Fry, C. J., Pearson, A., Malinowski, E., Bartley, S. M., Greenblatt, J., and
Farnham, P. J. (1999) J. Biol. Chem. 274, 15883–15891
43. Munshi, N., Agalioti, T., Lomvardas, S., Merika, M., Chen, G., and Thanos, D.
(2001) Science 293, 1133–1136
44. Barlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis,
T. D., and Berger, S. L. (2001) Mol. Cell 8, 1243–1254
45. Puri, P. L., Avantaggiati, M. L., Balsano, C., Sang, N., Graessmann, A.,
Giordano, A., and Levrero, M. (1997) EMBO J. 16, 369–383
46. Sartorelli, V., Puri, P. L., Hamamori, Y., Ogryzko, V., Chung, G., Nakatani, Y.,
Wang, J. Y. J., and Kedes, L. (1999) Mol. Cell 4, 725–734
47. Sciortino, S., Gurtner, A., Manni, I., Fontemaggi, G., Dey, A., Sacchi, A., Ozato,
K., and Piaggio, G. (2001) EMBO Rep. 2, 1018–1023
48. Arcot, S. S., Flemington, E. K., and Deininger, P. L. (1989) J. Biol. Chem. 264,
2343–2349
49. Park, J. B., and Levine, M. (2000) Biochem. Biophys. Res. Commun. 267,
651–657
NF-Y and p300 in Cell Cycle Regulation6650
 at U
N
IV
ERSITA
 D
I M
O
D
EN
A
 on M
ay 6, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Kurt Engeland and Roberto Mantovani
Valentina Salsi, Giuseppina Caretti, Mark Wasner, Wibke Reinhard, Ulrike Haugwitz,
Function
Interactions between p300 and Multiple NF-Y Trimers Govern Cyclin B2 Promoter
doi: 10.1074/jbc.M210065200 originally published online December 12, 2002
2003, 278:6642-6650.J. Biol. Chem. 
  
 10.1074/jbc.M210065200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/278/9/6642.full.html#ref-list-1
This article cites 49 references, 27 of which can be accessed free at
 at U
N
IV
ERSITA
 D
I M
O
D
EN
A
 on M
ay 6, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
